{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-072685","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.486120+00:00","generated_at":"2026-05-21T04:53:27.774946+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"TuHURA Q1 expenses rise; Phase 3 MCC trial and Kineta merger on track for Q2 2025","bullets":["Q1 2025 R&D expenses $4.6M (up 28% YoY); G&A $2.4M (up 140% YoY); shares outstanding ~43.7M.","Initiated Phase 1b/2a trial of IFx-Hu2.0 plus pembrolizumab in first-line Merkel cell carcinoma of unknown primary in May 2025.","Targeting Q2 2025 close of Kineta acquisition; Phase 2 trial of VISTA mAb in NPM1-mutated AML expected Q3 2025.","Phase 3 accelerated approval trial of IFx-Hu2.0 in advanced Merkel cell carcinoma expected to start Q2 2025 after lifting partial clinical hold.","Appointed Dr. Bertrand Le Bourdonnec as EVP Head of Drug Discovery in April 2025; Dr. Craig Tendler joined Board in March 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-072685","json":"https://secwatch.observer/filing/0000950170-25-072685.json","markdown":"https://secwatch.observer/filing/0000950170-25-072685.md","text":"https://secwatch.observer/filing/0000950170-25-072685.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017025072685/0000950170-25-072685-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017025072685/hura-20250515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:53:27.774946+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}